AbbVie beats expectations with smaller Humira slide — and big gains for next autoimmune blockbusters

Humira isn’t going anywhere yet. And its successors are coming along nicely, too.

On Thursday, AbbVie shared second-quarter financial results that show its cornerstone immunology …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Cano Health’s downfall offers a warning for Medicare Advantage

Private Medicare just isn’t the gold mine it once was. Case in point: Cano Health, a company once valued at $4.4 billion, is now bankrupt.

February 5, 2024

Arts and creativity interventions prove cost-effective for enhancing older adults’ health and well-being

Study in BMC Public Health evaluates the cost-effectiveness of arts and creativity interventions (ACIs) for older adults, revealing their positive impact on health and well-being,

December 19, 2023

State of Texas Develop Flu Tracking Dashboards for Prediction & Response

What You Should Know: Texas Department of State Health Services (TX DSHS) has partnered with SAS to develop new public health dashboards for tracking influenza

June 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.